Skip to main content
Top

06-02-2018 | Cardiovascular disorders | Article

Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA)

Journal: Cardiovascular Diabetology

Authors: Anthony Pease, Arul Earnest, Sanjeeva Ranasinha, Natalie Nanayakkara, Danny Liew, Natalie Wischer, Sofianos Andrikopoulos, Sophia Zoungas

Publisher: BioMed Central

Abstract

Background

Cardiovascular risk stratification is complex in type 1 diabetes. We hypothesised that traditional and diabetes-specific cardiovascular risk factors were prevalent and strongly associated with cardiovascular disease (CVD) among adults with type 1 diabetes attending Australian diabetes centres.

Methods

De-identified, prospectively collected data from patients with type 1 diabetes aged ≥ 18 years in the 2015 Australian National Diabetes Audit were analysed. The burden of cardiovascular risk factors [age, sex, diabetes duration, glycated haemoglobin (HbA1c), blood pressure, lipid profile, body mass index, smoking status, retinopathy, renal function and albuminuria] and associations with CVD inclusive of stroke, myocardial infarction, coronary artery bypass graft surgery/angioplasty and peripheral vascular disease were assessed. Restricted cubic splines assessed for non-linearity of diabetes duration and likelihood ratio test assessed for interactions between age, diabetes duration, centre type and cardiovascular outcomes of interest. Discriminatory ability of multivariable models were assessed with area under the receiver operating characteristic (ROC) curves.

Results

Data from 1169 patients were analysed. Mean (± SD) age and median diabetes duration was 40.0 (± 16.7) and 16.0 (8.0–27.0) years respectively. Cardiovascular risk factors were prevalent including hypertension (21.9%), dyslipidaemia (89.4%), overweight/obesity (56.4%), ever smoking (38.5%), albuminuria (31.1%), estimated glomerular filtration rate < 60 mL/min/1.73 m2 (10.3%) and HbA1c > 7.0% (53 mmol/mol) (81.0%). Older age, longer diabetes duration, smoking and antihypertensive therapy use were positively associated with CVD, while high density lipoprotein-cholesterol and diastolic blood pressure were negatively associated (p < 0.05). Association with CVD and diabetes duration remained constant until 20 years when a linear increase was noted. Longer diabetes duration also had the highest population attributable risk of 6.5% (95% CI 1.4, 11.6). Further, the models for CVD demonstrated good discriminatory ability (area under the ROC curve 0.88; 95% CI 0.84, 0.92).

Conclusions

Cardiovascular risk factors were prevalent and strongly associated with CVD among adults with type 1 diabetes attending Australian diabetes centres. Given the approximate J-shaped association between type 1 diabetes duration and CVD, the impact of cardiovascular risk stratification and management before and after 20 years duration needs to be further assessed longitudinally. Diabetes specific cardiovascular risk stratification tools incorporating diabetes duration should be an important consideration in future guideline development.
Literature
1.
National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012. https://​www.​aihw.​gov.​au/​getmedia/​0ce5f234-0abf-41b9-a392-be5dd1e94c54/​17034.​pdf.​aspx?​inline=​true. Accessed 5 Mar 2018.
2.
Australian Institute of Health and Welfare 2014. Cardiovascular disease, diabetes and chronic kidney disease—Australian facts: prevalence and incidence. Cardiovascular, diabetes and chronic kidney disease series no. 2. Cat. no. CDK 2. Canberra: AIHW. https://​www.​aihw.​gov.​au/​getmedia/​0ce5f234-0abf-41b9-a392-be5dd1e94c54/​17034.​pdf.​aspx?​inline=​true. Accessed 5 Mar 2018.
3.
Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;12(1):156.CrossRefPubMedPubMedCentral
4.
de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diab Care. 2014;37(10):2843–63.CrossRef
5.
Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46(6):760–5. https://​doi.​org/​10.​1007/​s00125-003-1116-6.CrossRefPubMed
6.
Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl 2):S14–21.CrossRefPubMed
7.
Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diab Care. 2006;29(4):798–804. http://​care.​diabetesjournals​.​org/​content/​29/​4/​798.​long. Accessed 15 May 2018.
8.
Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:S49–73. http://​circ.​ahajournals.​org/​content/​129/​25_​suppl_​2/​S49.​long. Accessed 16 May 2018.
9.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedPubMedCentral
10.
National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. Clinical guideline [CG181]. 2014. http://​www.​nice.​org.​uk/​Guidance/​CG181. Accessed 17 Feb 2018.
11.
Jaiswal M, Divers J, Urbina EM, Dabelea D, Bell RA, Pettitt DJ, et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for diabetes in youth cohort study. Pediatr Diab. 2018;19(4):680–9. https://​doi.​org/​10.​1111/​pedi.​12633.CrossRef
12.
Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006;49(2):298–305. https://​doi.​org/​10.​1007/​s00125-005-0082-6.CrossRefPubMed
13.
Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59(12):3216–22. http://​diabetes.​diabetesjournals​.​org/​content/​59/​12/​3216. Accessed 14 May 2018.
14.
Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation. 1983;67(5):968–77. http://​circ.​ahajournals.​org/​content/​67/​5/​968.​long. Accessed 12 May 2018.
15.
Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322(13):882–9. https://​doi.​org/​10.​1056/​NEJM199003293221​303.CrossRefPubMed
16.
Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–72. https://​jamanetwork.​com/​journals/​jamainternalmedi​cine/​fullarticle/​212796. Accessed 14 May 2018.
17.
Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.CrossRefPubMed
18.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364(9438):937–52. https://​www.​thelancet.​com/​journals/​lancet/​article/​PIIS0140-6736(04)17018-9/​fulltext. Accessed 14 May 2018.
19.
Craig ME, Twigg SM, Donaghue KC, Cheung NW, Cameron FJ, Conn J, et al for the Australian Type 1 Diabetes Guidelines Expert Advisory Group. National evidence-based clinical care guidelines for type 1 diabetes in children, adolescents and adults. In: Australian Government Department of Health and Ageing. Canberra 2011. https://​www.​nhmrc.​gov.​au/​_​files_​nhmrc/​publications/​attachments/​ext004_​type1_​diabetes_​children_​adolescents_​adults.​pdf. Accessed 5 Mar 2018.
20.
Zgibor JC, Piatt GA, Ruppert K, Orchard TJ, Roberts MS. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diab Care. 2006;29(8):1860–5. http://​care.​diabetesjournals​.​org/​content/​diacare/​29/​8/​1860.​full.​pdf. Accessed 10 May 2018.
21.
Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation. 2016;133(11):1058–66. http://​circ.​ahajournals.​org/​content/​133/​11/​1058.​long. Accessed 15 May 2018.
22.
Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdottir S. A new model for 5-year risk of cardiovascular disease in type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diab Med. 2011;28(10):1213–20. https://​doi.​org/​10.​1111/​j.​1464-5491.​2011.​03342.​x.CrossRef
23.
Zgibor JC, Ruppert K, Orchard TJ, Soedamah-Muthu SS, Fuller J, Chaturvedi N, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diab Res Clin Pract. 2010;88(3):314–21.CrossRef
24.
Hernández M, López C, Real J, Valls J, Ortega-Martinez de Victoria E, Vázquez F, et al. Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes. Cardiovasc Diabetol. 2017;16:94.CrossRefPubMedPubMedCentral
25.
Ferreira I, Hovind P, Schalkwijk CG, Parving HH, Stehouwer CDA, Rossing P. Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort. Diabetologia. 2018;61(1):231–41. https://​doi.​org/​10.​1007/​s00125-017-4470-5.CrossRefPubMed
26.
Bradley TJ, Slorach C, Mahmud FH, Dunger DB, Deanfield J, Deda L, et al. Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. Cardiovasc Diabetol. 2016;15:31.CrossRefPubMedPubMedCentral
27.
Swasey KK, Orchard TJ, Costacou T. Trends in cardiovascular risk factor management in type 1 diabetes by sex. J Diab Compl. 2018;32(4):411–7. https://​www.​jdcjournal.​com/​article/​S1056-8727(17)30931-5/​fulltext. Accessed 14 May 2018.
28.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral
29.
Maple-Brown LJ, Hughes JT, Ritte R, Barzi F, Hoy WE, Lawton PD, et al. Progression of kidney disease in indigenous Australians: the eGFR follow-up study. Clin J Am Soc Nephrol. 2016;11(6):993–1004.CrossRefPubMedPubMedCentral
30.
Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, et al. High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID Study. BMC Public Health. 2011;11(1):346.CrossRefPubMedPubMedCentral
31.
Johnson DW, Jones GRD, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012. 197(4):222–3. https://​www.​mja.​com.​au/​journal/​2012/​197/​4/​chronic-kidney-disease-and-automatic-reporting-estimated-glomerular-filtration. Accessed 4 May 2018.
32.
Gordis L. Epidemiology. 2nd ed. Philadelphia: W.B. Saunders Company; 2000.
33.
Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://​www.​nejm.​org/​doi/​10.​1056/​NEJM199309303291​401?​url_​ver=​Z39.​88-2003&​rfr_​id=​ori:​rid:​crossref.​org&​rfr_​dat=​cr_​pub%3dwww.​ncbi.​nlm.​nih.​gov. Accessed 14 May 2018.
34.
Morimoto A, Onda Y, Nishimura R, Sano H, Utsunomiya K, Tajima N. Cause-specific mortality trends in a nationwide population-based cohort of childhood-onset type 1 diabetes in Japan during 35 years of follow-up: the DERI mortality study. Diabetologia. 2013;56(10):2171–5. https://​doi.​org/​10.​1007/​s00125-013-3001-2.CrossRefPubMed
35.
Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.CrossRefPubMedPubMedCentral
36.
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62(5):707–14. https://​www.​amjmed.​com/​article/​0002-9343(77)90874-9/​pdf. Accessed 15 May 2018.
37.
Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis. 2009;206(2):611–6. https://​www.​atherosclerosis-journal.​com/​article/​S0021-9150(09)00163-4/​fulltext. Accessed 14 May 2018.
38.
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.CrossRefPubMed
39.
Emerging risk factors collaboration, De Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499–506.
40.
Heier M, Borja MS, Brunborg C, Seljeflot I, Margeirsdottir HD, Hanssen KF, et al. Reduced HDL function in children and young adults with type 1 diabetes. Cardiovasc Diabetol. 2017;16:85.CrossRefPubMedPubMedCentral
41.
Propsective studies collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39. https://​www.​thelancet.​com/​journals/​lancet/​article/​PIIS0140-6736(07)61778-4/​fulltext. Accessed 14 May 2018.
42.
Adler AI, Erqou S, Lima TA, Robinson AH. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. Diabetologia. 2010;53(5):840–9. https://​doi.​org/​10.​1007/​s00125-009-1638-7.CrossRefPubMed
43.
Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes. 2002;51(8):2637–41. http://​diabetes.​diabetesjournals​.​org/​content/​51/​8/​2637.​long. Accessed 15 May 2018.
44.
Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, et al. Glycemic control and cardiovascular disease in 7454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diab Care. 2010;33(7):1640–6.CrossRef
45.
Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham heart study. Diabetes. 1992;41(2):202–8. http://​diabetes.​diabetesjournals​.​org/​content/​41/​2/​202.​long. Accessed 14 May 2018.
46.
Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G. HbA1c and coronary heart disease risk among diabetic patients. Diab Care. 2014;37(2):428–35.CrossRef
47.
Chen YY, Lin YJ, Chong E, Chen PC, Chao TF, Chen SA, et al. The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. PLoS ONE. 2015;10(4):e0123116. http://​journals.​plos.​org/​plosone/​article?​id=​10.​1371/​journal.​pone.​0123116. Accessed 14 May 2018.
48.
Miller RG, Anderson SJ, Costacou T, Sekikawa A, Orchard TJ. Hemoglobin A1c and cardiovascular disease incidence in type 1 diabetes: an application of joint modeling of longitudinal and time-to-event data in the pittsburgh epidemiology of diabetes complications (EDC) study. Am J Epidemiol. 2018. https://​academic.​oup.​com/​aje/​advance-article-abstract/​doi/​10.​1093/​aje/​kwx386/​4831247?​redirectedFrom=​fulltext. Accessed 15 May 2018. (Epub ahead of print).
49.
Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess. 2005;9(30):iii–vi, xiii–163. https://​www.​journalslibrary.​nihr.​ac.​uk/​hta/​hta9300#/​full-report. Accessed 15 May 2018.
50.
Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7(6):930–7. http://​jasn.​asnjournals.​org/​content/​7/​6/​930.​long. Accessed 15 May 2018.
51.
Australian Institute of Health and Welfare 2017. National Drug Strategy Household Survey 2016: detailed findings. Drug Statistics series no. 31. Cat. no. PHE 214. Canberra: AIHW. https://​www.​aihw.​gov.​au/​getmedia/​15db8c15-7062-4cde-bfa4-3c2079f30af3/​21028.​pdf.​aspx?​inline=​true. Accessed 5 Mar 2018.
52.
Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diab Care. 2017;40(12):1756–62. http://​care.​diabetesjournals​.​org/​content/​40/​12/​1756.​long. Accessed 15 May 2018.
53.
Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diab Med. 2010;27(4):398–404.CrossRef
54.
Price SA, Gorelik A, Fourlanos S, Colman PG, Wentworth JM. Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes. Obes Res Clin Pract. 2014;8(2):e178–82. https://​www.​obesityresearchc​linicalpractice.​com/​article/​S1871-403X(13)00032-X/​fulltext. Accessed 15 May 2018.
55.
Holt SK, Lopushnyan N, Hotaling J, Sarma AV, Dunn RL, Cleary PA, et al. Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC. J Clin Endocrinol Metab. 2014;99(9):E1655–60.CrossRefPubMedPubMedCentral
56.
Franklin SS. Beyond blood pressure: arterial stiffness as a new biomarker of cardiovascular disease. J Am Soc Hypertens. 2008;2(3):140–51. https://​www.​ashjournal.​com/​article/​S1933-1711(07)00194-5/​fulltext. Accessed 15 May 2018.
57.
Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the Framingham heart study. Glob Heart. 2013;8(1):49–57. https://​www.​sciencedirect.​com/​science/​article/​pii/​S221181601200264​5?​via%3Dihub. Accessed 15 May 2018.
58.
Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60(16):1455–69. https://​www.​sciencedirect.​com/​science/​article/​pii/​S073510971202523​5?​via%3Dihub. Accessed 15 May 2018.
59.
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351(9118):1755–62. https://​www.​thelancet.​com/​journals/​lancet/​article/​PIIS0140-6736(98)04311-6/​fulltext. Accessed 15 May 2018.
60.
SPRINT Research Group, Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. https://​www.​nejm.​org/​doi/​10.​1056/​NEJMoa1511939?​url_​ver=​Z39.​88-2003&​rfr_​id=​ori:​rid:​crossref.​org&​rfr_​dat=​cr_​pub%3dwww.​ncbi.​nlm.​nih.​gov. Accessed 15 May 2018.
61.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil–trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–16. https://​jamanetwork.​com/​journals/​jama/​fullarticle/​197761. Accessed 15 May 2018.
62.
Satish S, Zhang DD, Goodwin JS. Clinical significance of falling blood pressure among older adults. J Clin Epidemiol. 2001;54(9):961–7. https://​www.​jclinepi.​com/​article/​S0895-4356(01)00360-2/​fulltext. Accessed 15 May 2018.
63.
Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142–52. https://​www.​thelancet.​com/​journals/​lancet/​article/​PIIS0140-6736(16)31326-5/​fulltext. Accessed 15 May 2018.
64.
Mohammedi K, Potier L, Belhatem N, Matallah N, Hadjadj S, Roussel R, et al. Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. Cardiovasc Diabetol. 2016;15:5.CrossRefPubMedPubMedCentral
65.
Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Williams B, Lisheng L, et al. Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes. Diab Care. 2016;39(10):1796–803. http://​care.​diabetesjournals​.​org/​content/​39/​10/​1796.​long. Accessed 15 May 2018.
66.
Garimella PS, Hart PD, O’Hare A, DeLoach S, Herzog CA, Hirsch AT. Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. Am J Kidney Dis. 2012;60(4):641–54. https://​www.​ajkd.​org/​article/​S0272-6386(12)00665-8/​fulltext. Accessed 15 May 2018.
67.
Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol. 2008;52(21):1736–42. https://​www.​sciencedirect.​com/​science/​article/​pii/​S073510970802959​8?​via%3Dihub. Accessed 15 May 2018.
68.
Chronic kidney disease prognosis consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. https://​www.​thelancet.​com/​journals/​lancet/​article/​PIIS0140-6736(10)60674-5/​fulltext. Accessed 15 May 2018.
69.
Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015;30(7):1162–9. https://​academic.​oup.​com/​ndt/​article/​30/​7/​1162/​2324840. Accessed 15 May 2018.
70.
Ovbiagele B, Bath PM, Cotton D, Sha N, Diener HC, PRoFESS investigators. Low glomerular filtration rate, recurrent stroke risk, and effect of renin-angiotensin system modulation. Stroke. 2013;44(11):3223–5. http://​stroke.​ahajournals.​org/​content/​44/​11/​3223.​long. Accessed 15 May 2018.
71.
Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Kidney Int. 2003;64(2):610–5. https://​www.​kidney-international.​org/​article/​S0085-2538(15)49368-8/​fulltext. Accessed 15 May 2018.
72.
Sandsmark DK, Messe SR, Zhang X, Roy J, Nessel L, Lee Hamm L, et al. Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease: chronic renal insufficiency cohort study. Stroke. 2015;46(8):2075–80.CrossRefPubMedPubMedCentral
73.
Bouchi R, Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, et al. Is a reduced estimated glomerular filtration rate a risk factor for stroke in patients with type 2 diabetes? Hypertens Res. 2009;32(5):381–6. https://​www.​nature.​com/​articles/​hr200930. Accessed 15 May 2018.
74.
Sundquist K, Li X. Type 1 diabetes as a risk factor for stroke in men and women aged 15–49: a nationwide study from Sweden. Diab Med. 2006;23(11):1261–7. https://​doi.​org/​10.​1111/​j.​1464-5491.​2006.​01959.​x.CrossRef
75.
Hagg S, Thorn LM, Putaala J, Liebkind R, Harjutsalo V, Forsblom CM, et al. Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diab Care. 2013;36(12):4140–6. http://​care.​diabetesjournals​.​org/​content/​36/​12/​4140.​long. Accessed 15 May 2018.
76.
Chang YT, Wu JL, Hsu CC, Wang JD, Sung JM. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998–2009. Diab Care. 2014;37(1):277–85. http://​care.​diabetesjournals​.​org/​content/​37/​1/​277.​long. Accessed 16 May 2018.
77.
Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C, et al. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia. 1998;41(7):784–90. https://​doi.​org/​10.​1007/​s001250050988.CrossRefPubMed
78.
Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73. http://​annals.​org/​aim/​fullarticle/​2088542/​transparent-reporting-multivariable-prediction-model-individual-prognosis-diagnosis-tripod-explanation. Accessed 15 May 2018.

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »